Valiant Laboratories Ltd

Valiant Laborato Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Valiant Laboratories Ltd

₹ 104 -0.94%
21 May - close price
valiantlabs.in BSE: 543998 NSE: VALIANTLAB
About

Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]

Key Points

Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever

Website BSE NSE - BE
  • Market Cap ₹ 441 Cr.
  • Current Price ₹ 104
  • High / Low ₹ 158 / 75.2
  • Stock P/E
  • Book Value ₹ 53.9
  • Dividend Yield 0.00 %
  • ROCE -0.40 %
  • ROE -0.93 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 197 days.
  • Working capital days have increased from 127 days to 203 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
87.96 70.77 89.92 51.41 59.55 40.52 30.59 18.88 21.48 35.23 57.79
77.28 60.84 81.30 47.59 60.94 46.83 35.12 21.27 28.22 34.61 53.97
Operating Profit 10.68 9.93 8.62 3.82 -1.39 -6.31 -4.53 -2.39 -6.74 0.62 3.82
OPM % 12.14% 14.03% 9.59% 7.43% -2.33% -15.57% -14.81% -12.66% -31.38% 1.76% 6.61%
1.47 0.78 1.72 2.44 2.96 1.78 2.50 2.81 3.36 1.58 -2.31
Interest 0.17 0.04 0.03 0.02 0.02 0.02 0.02 0.05 0.01 0.06 0.05
Depreciation 0.37 0.40 0.44 0.46 0.49 0.49 0.52 0.53 0.52 0.52 0.52
Profit before tax 11.61 10.27 9.87 5.78 1.06 -5.04 -2.57 -0.16 -3.91 1.62 0.94
Tax % 25.50% 25.51% 20.67% 26.12% 25.47% -30.75% -51.75% 218.75% 21.23% -44.44% 25.53%
8.66 7.65 7.83 4.27 0.79 -3.50 -1.24 -0.51 -4.74 2.35 0.70
EPS in Rs 5.32 4.70 2.40 1.31 0.24 -0.81 -0.29 -0.12 -1.09 0.54 0.16
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
334 182 133
299 190 138
Operating Profit 35 -8 -5
OPM % 11% -5% -4%
5 10 5
Interest 0 0 0
Depreciation 2 2 2
Profit before tax 38 -1 -2
Tax % 24% -142% 46%
29 0 -2
EPS in Rs 8.91 0.07 -0.51
Dividend Payout % 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -27%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 24%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -28%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: -1%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
Equity Capital 33 43 43
Reserves 68 193 191
60 77 122
52 29 45
Total Liabilities 213 343 401
48 50 48
CWIP 1 43 156
Investments 34 38 4
130 212 193
Total Assets 213 343 401

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
56 2 1
-55 -144 -53
-1 152 45
Net Cash Flow -0 10 -7

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
Debtor Days 97 92 197
Inventory Days 17 22 12
Days Payable 62 56 127
Cash Conversion Cycle 52 57 82
Working Capital Days 71 109 203
ROCE % -2% -0%

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94%
8.64% 7.08% 3.48% 1.89% 0.00% 0.00% 0.64%
1.76% 0.43% 0.00% 0.00% 0.00% 0.00% 0.00%
14.66% 17.54% 21.58% 23.18% 25.06% 25.06% 24.42%
No. of Shareholders 37,43415,82114,91414,24915,18915,69215,036

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings